Compare Crispr Therapeutics AG (CRSP) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Micron Technology, Inc. — how do they compare? Crispr Therapeutics AG trades at $51.36 (market cap $4.97B), while Micron Technology, Inc. trades at $902.79 (market cap $1.11T). The key difference: Micron Technology, Inc. is far larger — about 223.3× Crispr Therapeutics AG's market cap, and Micron Technology, Inc. pays a 0.05% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MU | |
|---|---|---|
Market Cap | $4.97B | $1.11T |
Sector | Health | Technology |
52-Week High | $76.78 | $1.21K |
52-Week Low | $44.34 | $104.88 |
Enterprise Value | $3.32B | $1.09T |
Dividend Yield | — | 0.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Micron Technology (MU) trades at $937.00, down 4.32% today, but maintains strong bullish technical momentum with support near $924. The company demonstrates robust fundamentals, with Q1 2026 EPS beating estimates at $25.11 versus $20.98 expected, and revenue growth accelerating to $37.38 billion in 2025. Analyst sentiment remains overwhelmingly positive, with 81% recommending Buy and a consensus price target of $1,550.
Outlook is favorable driven by AI memory demand and pricing power, though risks include competitive pressure from SK Hynix and cyclical semiconductor volatility. Cash flow trends show strengthening operational performance, with net cash flow turning positive at $2.59 billion in 2025, supporting future growth investments and shareholder returns via dividends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
